Abiomed
Presence
Johnson & Johnson is one of the...
- Forbes Global 2000 (#45);
- Fortune 500 (#42);
- Global Fortune 500 (#115);
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Johnson & Johnson is a company listed under the stock ticker JNJ (US).
Johnson & Johnson has a direct presence in 23 countries.Johnson & Johnson has 65 subsidiaries including Abiomed, Ambrx and DePuy Synthes.
They are in:
- Pharmaceuticals61%
- Medical Equipment18%
- Other21%
Acquisition, funding and merger involving Johnson & Johnson.
- Johnson & Johnson has announced the acquisition of Abiomed (posted on November 1 2022).
Executives
View the org chart displaying its 12 main executives
Most searched biographies at Abiomed
- Andrew Greenfield, President
- Nonna Akopyan, Head of Legal
- Thorsten Siess, Executive Vice President, Managing Director and Ch...
Popular executive movements at Johnson & Johnson
- Scott Davis, Director, is retiring (posted on September 11 2024).
- Kristen Mulholland who is Head of Human Resources, Global Total Rewards, will be promoted to Chief Human Resources Officer on Oct. 1, 2024 (posted on August 26 2024).
- Peter Fasolo, Executive Vice President and Chief Human Resources Officer, will retire on Oct. 1, 2024 (posted on August 26 2024).
Create your alert
to follow the executive moves at Abiomed.
Medical Equipment
Johnson & Johnson has 987 competitors including Philips (Netherlands), Medtronic (Ireland) and Thermo Fisher Scientific (United States (USA)).
Popular M&A news in Medical Equipment
- Johnson & Johnson has acquired V-Wave (posted on October 9 2024).
- Biolase Technology has filed for bankruptcy protection Biolase Technology (posted on October 2 2024).
- Mendaera has just announced a $73 Million fundraising (posted on October 1 2024).
Popular contacts in Medical Equipment
News
Press releases by Abiomed
- Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
- ERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer
- DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma
- Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
- RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
- RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
- New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
- Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
- European Commission approves RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer after failure of prior therapy
- View more press releases Close
Social media about Abiomed
- Abiomed on Wikipedia, Google News & Yahoo Finance
- Abiomed on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Andrew Greenfield 
